Sanofi SA Company Profile (EPA:SAN)

About Sanofi SA (EPA:SAN)

Sanofi SA logoSanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company's segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company's pharmaceuticals operations. The Vaccines segment is dedicated to vaccines and includes the commercial operations of the Company's vaccines division Sanofi Pasteur and dedicated research and development, production and marketing activities for the Company's vaccines operations. Its Rare Diseases products include Cerezyme, Cerdelga, Myozyme and Lumizyme, Fabrazyme, and Aldurazyme.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Symbol: EPA:SAN
  • CUSIP: N/A
  • Web: en.sanofi.com
Average Prices:
  • 50 Day Moving Avg: €26.12
  • 200 Day Moving Avg: €25.99
P/E:
  • Trailing P/E Ratio: 11.49
  • P/E Growth: 2.24
Dividend:
  • Dividend Yield: 1.0%
Profitability:
  • Net Margins: 11.65%
 

Frequently Asked Questions for Sanofi SA (EPA:SAN)

What is Sanofi SA's stock symbol?

Sanofi SA trades on the EPA under the ticker symbol "SAN."

Where is Sanofi SA's stock going? Where will Sanofi SA's stock price be in 2017?

16 brokers have issued 1-year target prices for Sanofi SA's shares. Their predictions range from €75.00 to €100.00. On average, they expect Sanofi SA's stock price to reach €88.20 in the next twelve months. View Analyst Ratings for Sanofi SA.

Who are some of Sanofi SA's key competitors?

Who are Sanofi SA's key executives?

Sanofi SA's management team includes the folowing people:

  • Serge Weinberg, Independent Chairman of the Board
  • Olivier Brandicourt, Chairman of the Executive Committee, Chief Executive Officer, Director
  • Jerome Contamine, Executive Vice President, Chief Financial Officer, Member of the Executive Committee and the Senior Leadership Team
  • Karen Marie Linehan, Executive Vice President, Legal Affairs and General Counsel, Member of the Executive Committee and the Senior Leadership Team
  • Olivier Charmeil, Executive Vice President and General Manager, General Medicines & Emerging Markets, Member of the Executive Committee and the Senior Leadership Team
  • Peter Guenter, Executive Vice President and General Manager, Diabetes & Cardiovascular, Member of the Executive Committee and the Senior Leadership Team
  • Carsten Hellmann, Executive Vice President and General Manager of Merial, Member of the Executive Committee and the Senior Leadership Team
  • David Loew, Executive Vice President and General Manager of Sanofi Pasteur, Member of the Executive Committee and the Senior Leadership Team
  • David P. Meeker M.D., Executive Vice President and General Manager of Sanofi Genzyme, Member of the Executive Committee and the Senior Leadership Team
  • Roberto Pucci, Executive Vice President, Human Resources, Member of the Executive Committee and the Senior Leadership Team


MarketBeat Community Rating for Sanofi SA (EPA SAN)
Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  347 (Vote Outperform)
Underperform Votes:  426 (Vote Underperform)
Total Votes:  773
MarketBeat's community ratings are surveys of what our community members think about Sanofi SA and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Sanofi SA (EPA:SAN) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 1 Sell Rating, 10 Hold Ratings, 5 Buy Ratings
Consensus Rating:Hold (Score: 2.25)
Consensus Price Target: €88.20

Analysts' Ratings History for Sanofi SA (EPA:SAN)
Show:
DateFirmActionRatingPrice TargetDetails
9/18/2017Jefferies Group LLCSet Price TargetNeutral€86.00View Rating Details
9/14/2017J P Morgan Chase & CoSet Price TargetNeutral€85.00View Rating Details
9/12/2017HSBC Holdings plcSet Price TargetNeutral€81.00View Rating Details
9/12/2017BNP ParibasSet Price TargetNeutral€85.00View Rating Details
9/7/2017Kepler Capital MarketsSet Price TargetBuy€90.00View Rating Details
8/7/2017Goldman Sachs Group, Inc. (The)Set Price TargetNeutral€82.00View Rating Details
8/1/2017Deutsche Bank AGSet Price TargetBuy€96.00View Rating Details
7/31/2017Sanford C. BernsteinSet Price TargetNeutral€90.00View Rating Details
7/31/2017Berenberg BankSet Price TargetNeutral€97.00View Rating Details
7/31/2017S&P GlobalSet Price TargetNeutral€90.00View Rating Details
7/4/2017Credit Suisse GroupSet Price TargetBuy€95.00View Rating Details
6/6/2017Morgan StanleySet Price TargetBuy€91.00View Rating Details
5/8/2017Barclays PLCSet Price TargetSell€75.00View Rating Details
3/23/2017Societe GeneraleSet Price TargetBuy€100.00View Rating Details
1/6/2017Citigroup Inc.Reiterated RatingNeutralView Rating Details
12/6/2016S&P Global Inc.Set Price TargetNeutral€80.00View Rating Details
6/30/2016Independent Research GmbHSet Price TargetNeutral€77.00View Rating Details
6/9/2016Baader BankSet Price TargetNeutral€78.00View Rating Details
2/9/2016S&P Equity ResearchSet Price TargetBuy€85.00View Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Sanofi SA (EPA:SAN)
No earnings announcements for this company have been tracked by MarketBeat.com

Estimates

Earnings Estimates for Sanofi SA (EPA:SAN)

No earnings estimates for this company have been tracked by MarketBeat.com

Dividends

Dividend History for Sanofi SA (EPA:SAN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Sanofi SA (EPA:SAN)
No insider trades for this company have been tracked by MarketBeat.com

Headlines

Headline Trends for Sanofi SA (EPA:SAN)
Latest Headlines for Sanofi SA (EPA:SAN)
Source:
DateHeadline
finance.yahoo.com logoWhy Exelixis Wouldn't Be a Warren Buffett Stock
finance.yahoo.com - September 20 at 8:40 AM
finance.yahoo.com logoAlnylam and Sanofi Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
finance.yahoo.com - September 20 at 8:40 AM
finance.yahoo.com logoSanofi and Alnylam Report Positive Topline Results from APOLLO Phase 3 Study of Patisiran in Hereditary ATTR (hATTR) Amyloidosis Patients with Polyneuropathy
finance.yahoo.com - September 20 at 8:40 AM
finance.yahoo.com logoUPDATE: Alnylam shares jump 24% on positive results from late-stage trial of hATTR amyloidosis treatment
finance.yahoo.com - September 20 at 8:40 AM
americanbankingnews.com logoJefferies Group LLC Analysts Give Sanofi SA (SAN) a €86.00 Price Target
www.americanbankingnews.com - September 18 at 6:30 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €85.00 Price Target at J P Morgan Chase & Co
www.americanbankingnews.com - September 17 at 1:32 PM
News IconUPDATE 1-Lilly/Incyte pill beats placebo in mid-stage eczema trial
www.businessinsider.com - September 16 at 8:27 AM
finance.yahoo.com logoPatient-Driven Dose Titration with Sanofi's Toujeo Improved Blood Glucose Control Without Increasing Hypoglycemia Risk in Real-Life Clinical Practice
finance.yahoo.com - September 14 at 9:45 AM
reuters.com logoRegeneron, Sanofi asthma drug data fails to excite investors - Reuters
www.reuters.com - September 12 at 9:28 AM
finance.yahoo.com logoSanofi's Soliqua® 100/33 Provided Earlier Blood Sugar Control than Insulin Glargine 100 Units/mL
finance.yahoo.com - September 12 at 9:28 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €83.00 Price Target at BNP Paribas
www.americanbankingnews.com - September 10 at 8:52 PM
benzinga.com logoWhat Pharmaceuticals Spend On Lobbying To Influence Trump - Benzinga
www.benzinga.com - September 10 at 7:15 AM
cnn.com logoSanofi stops work on Zika vaccine while others forge forward
www.cnn.com - September 8 at 7:59 AM
americanbankingnews.com logoSanofi SA (SAN) Earns "Neutral" Rating from J P Morgan Chase & Co
www.americanbankingnews.com - September 8 at 6:22 AM
reuters.com logoQuest to offer cholesterol testing without fasting requirement - Reuters
www.reuters.com - September 7 at 8:39 AM
wsj.com logoSanofi Stops Work on Two Zika Vaccines - Wall Street Journal (subscription)
www.wsj.com - September 7 at 8:39 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €90.00 Price Target by Kepler Capital Markets Analysts
www.americanbankingnews.com - September 7 at 7:18 AM
finance.yahoo.com logoWhy Is Regeneron (REGN) Up 7.9% Since the Last Earnings Report?
finance.yahoo.com - September 5 at 7:53 AM
benzinga.com logoThe Pullback In Sanofi Is A Buying Opportunity, Says Argus - Benzinga
www.benzinga.com - September 2 at 8:18 AM
finance.yahoo.com logoThe Pullback In Sanofi Is A Buying Opportunity, Says Argus
finance.yahoo.com - September 2 at 8:18 AM
americanbankingnews.com logoSanofi SA (SAN) Receives Average Rating of "Hold" from Brokerages
www.americanbankingnews.com - August 29 at 8:44 AM
nasdaq.com logoSanofi Closes Acquisition Of Influenza Vaccine Developer Protein Sciences - Nasdaq
www.nasdaq.com - August 29 at 7:31 AM
rttnews.com logoSanofi Closes Acquisition Of Influenza Vaccine Developer Protein Sciences
www.rttnews.com - August 28 at 6:19 AM
seekingalpha.com logoSanofi Takes A Multipronged Approach To Maintaining Its Dividend Performance
seekingalpha.com - August 25 at 11:11 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €87.00 Price Target at Jefferies Group LLC
www.americanbankingnews.com - August 24 at 3:22 PM
finance.yahoo.com logoPerformance of Sanofi’s Established Products in 2Q17
finance.yahoo.com - August 19 at 7:15 AM
finance.yahoo.com logoSanofi’s General Medicines and Consumer Healthcare in 2Q17
finance.yahoo.com - August 19 at 7:15 AM
finance.yahoo.com logoA Look at Sanofi Pasteur’s Performance in 2Q17
finance.yahoo.com - August 19 at 7:15 AM
benzinga.com logoWhere Does Zika Virus Vaccine Research Stand Now? - Benzinga
www.benzinga.com - August 14 at 3:00 AM
reuters.com logoMexico watchdog finds big pharma faces no competition on some ... - Reuters
www.reuters.com - August 10 at 7:39 AM
News IconCVS Health's dull third-quarter forecast overshadows profit beat - Business Insider
www.businessinsider.com - August 9 at 7:09 AM
finance.yahoo.com logoSanofi Files Suit in the U.S. to Defend its Patent Rights on Lantus®
finance.yahoo.com - August 9 at 7:09 AM
americanbankingnews.com logoGoldman Sachs Group, Inc. (The) Analysts Give Sanofi SA (SAN) a €82.00 Price Target
www.americanbankingnews.com - August 7 at 9:20 PM
benzinga.com logoThis Week's Pharma, Energy IPOs - Benzinga
www.benzinga.com - August 7 at 3:18 PM
americanbankingnews.com logoSanofi SA (SAN) Given Average Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - August 4 at 10:44 AM
reuters.com logoRegeneron beats profit view, to end antibody deal with Sanofi - Reuters
www.reuters.com - August 4 at 7:51 AM
finance.yahoo.com logoRegeneron quarterly profit nearly doubles
finance.yahoo.com - August 4 at 7:51 AM
finance.yahoo.com logoRegeneron: Wait, I Thought It Was Good News?!?!
finance.yahoo.com - August 4 at 7:51 AM
nasdaq.com logoEurope ETF (EZU) Hits New 52-Week High - Nasdaq
www.nasdaq.com - August 2 at 10:30 PM
thestreet.com logoSanofi Is Selling a Ton of Vaccines So It Decided to Hike Its Profit Outlook - TheStreet.com
www.thestreet.com - August 2 at 7:28 AM
americanbankingnews.com logoDeutsche Bank AG Reiterates "€96.00" Price Target for Sanofi SA (EPA:SAN)
www.americanbankingnews.com - August 1 at 12:56 PM
seekingalpha.com logoSanofi (SNY) Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 1 at 6:10 AM
rttnews.com logoSanofi Q2 Profit Down, Sales Rise; Lifts FY17 Earnings View; Stock Up
www.rttnews.com - August 1 at 6:10 AM
finance.yahoo.com logoBiotech Is Only Expensive When You Follow the Crowd
finance.yahoo.com - August 1 at 6:10 AM
finance.yahoo.com logoPraluent Could Witness Steady Growth in 2017
finance.yahoo.com - August 1 at 6:10 AM
finance.yahoo.com logoEdited Transcript of SAN.PA earnings conference call or presentation 31-Jul-17 12:30pm GMT
finance.yahoo.com - August 1 at 6:10 AM
finance.yahoo.com logoSanofi meets 2Q profit forecasts
finance.yahoo.com - August 1 at 6:10 AM
americanbankingnews.com logoSanofi SA (SAN) Given a €97.00 Price Target by Berenberg Bank Analysts
www.americanbankingnews.com - July 31 at 12:21 PM
americanbankingnews.com logoSanford C. Bernstein Analysts Give Sanofi SA (EPA:SAN) a €90.00 Price Target
www.americanbankingnews.com - July 31 at 11:11 AM
nasdaq.com logoSanofi Q2 Profit Declines, Sales Rise; Lifts FY17 Business EPS View - Nasdaq
www.nasdaq.com - July 31 at 2:30 AM

Social

Social activity is not available for this stock.
This page was last updated on 9/21/2017 by MarketBeat.com Staff